Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthLucet Electroconvulsive Therapy Coverage Prior Aut…
    Ask Trek AI about this page
    CurrentlucetPolicy 20.5.002

    Electroconvulsive Therapy (ECT) - 2024

    Customize your policy alerts

    Sign up for lucet Policy 20.5.002 alerts

    Get alerted when Policy 20.5.002 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, authorization, and clinical requirements for ECT benefit approval for Lucet members and providers during plan year 2024.

    Policy Summary
    Payerlucet
    PolicyElectroconvulsive Therapy (ECT) - 2024
    Policy CodePolicy 20.5.002
    Change TypeNo material changes
    Effective DateAug 21, 2024
    Last ReviewSep 23, 2023
    Next Review DateSep 23, 2023
    Key ActionObtain prior authorization documenting required clinical criteria and request twelve (12) units of CPT 90870 for initial ECT when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12Initial authorization units
    6-12Typical total treatments
    3-5/week

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Acute treatment frequency
    13+FDA cleared age
    Up to 6 monthsContinuation period

    Coverage Criteria for ECT

    inv-01: Initial Authorization

    Covered when ALL of the following are met

    Initial Authorization Requirements: Must meet all of the following i–vi
    Diagnoses (i): Primary DSM diagnosis must be one of: Major Depressive Disorder (single or recurrent; severe, psychotic, or non-psychotic), Bipolar Disorder (depressed, mixed, manic), Schizophrenia/Schizophrenia Spectrum/Schizoaffective/Psychotic Disorders, Catatonia, Neuroleptic Malignant Syndrome
    Expectation and evaluation (ii–iii): There is a reasonable expectation of reduction in severity with ECT AND a complete diagnostic psychiatric evaluation is completed prior to initiation
    Prior treatment or urgency (iv): One of: (1) documentation of two or more adequate trials of full-dose antidepressants (adequate time = 8 weeks) with augmentation tried/considered or inability to tolerate medications; OR (2) member is markedly impaired with high risk of serious physiological/physical complications; OR (3) history of significant prior response to ECT

    Acute treatment frequency typically 3–5 times/week

    Frequency and consent (v–vi): Frequency typically three times weekly AND member/guardian provides informed consent and is educated regarding risks and benefits

    inv-02: Continued Authorization

    Covered when ALL of the following are met

    Continued Authorization Requirements: Must meet all of the following a–d
    Diagnoses (a): Primary DSM diagnosis must be one of: Major Depressive Disorder; Bipolar Disorder; Schizophrenia/Schizophrenia Spectrum/Schizoaffective/Psychotic Disorders; Catatonia; Neuroleptic Malignant Syndrome
    Treatment compliance and expectation (b–c): Compliance with treatment plan unless clinically precluded AND reasonable expectation of improvement with continued ECT
    Progress documentation (d): Documentation of member progress toward objective, measurable treatment goals required; if not progressing, evidence of timely reevaluation and treatment plan modification

    inv-03: Continuation ECT (up to 6 months)

    Continuation ECT Requirements: Must meet all of the following i–iii

    Continuation refers to treatments after index series for up to 6 months to individuals in remission

    Attending psychiatrist assessment (i): Attending must assess current symptoms and medications, determine need for continuation ECT, and determine timing and frequency
    Response requirement (ii): Member has shown an adequate response to the index episode of ECT
    Preference or intolerance (iii): Member expresses preference for continuation ECT OR member is intolerant to pharmacotherapy

    inv-04: Maintenance ECT (post-continuation)

    Maintenance ECT Requirements: Must meet all of the following i–v

    Maintenance ECT is prophylactic after the 6-month continuation period; limited evidence for duration/efficacy

    Attending psychiatrist assessment (i): Attending must assess current symptoms and medications, determine need for Maintenance ECT, and determine timing and frequency
    Response requirement (ii): Member has shown an adequate response to continuation ECT
    Relapse history (iii): Member has marked history of relapse/recurrence OR history of significant symptom increase when Continuation ECT was tapered
    Preference or intolerance (iv):

    Facility and attending requirements: The primary attending physician must be a psychiatrist who is trained and credentialed to administer ECT and is responsible for the diagnostic evaluation and face-to-face services with documentation. The attending and facility must meet all applicable state laws and regulations regarding the practice of ECT. The FDA has granted clearance for ECT devices for individuals aged 13 and older, and special attention to informed consent is required for adolescents. ECT is typically administered in an inpatient or outpatient facility; in some cases members at a Residential level of care may receive ECT rendered at an outpatient facility. The total number of treatments in an index series is typically 6–12, guided by the clinical situation.

    Use beyond described indications or without meeting required documentation is not supported. Requests for ECT that do not meet the specified diagnostic indications (e.g., Major Depressive Disorder, Bipolar Disorder, Schizophrenia spectrum disorders, Catatonia, Neuroleptic Malignant Syndrome), lack a complete diagnostic psychiatric evaluation, fail to document required treatment history (such as two or more adequate trials of full‑dose antidepressants when indicated), are missing informed consent, or lack progress documentation as specified in the Continued Authorization requirements would be considered not medically necessary.

    Continuation and maintenance uses also have defined requirements: Continuation ECT is limited to treatments after the index series for up to 6 months and requires attending assessment, documented adequate response to the index episode, and member preference or intolerance to pharmacotherapy. Maintenance ECT (post-continuation) requires attending assessment, demonstrated adequate response to continuation ECT, a marked history of relapse/recurrence (or symptom increase when tapering), member preference or intolerance to pharmacotherapy, and documented informed consent; uses outside these parameters are not supported.

    CPT and Coding Details

    Covered CPT CodesCPTCovered
    90870ECT, general anesthesia
    Adequate antidepressant trial duration — 8 weeks
    Adequate antidepressant trial durationEight (8) weeks per antidepressant trial
    Number of adequate trials requiredTwo or more adequate trials of full‑dose antidepressants (unless alternative criteria apply)
    Augmentation considerationAugmentation with lithium, thyroid, or atypical antipsychotics has been tried or considered
    Exception to medication trialsDocumented inability to tolerate medications due to serious side effects may substitute

    Provider Requirements and Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization required for initial ECT. Initial authorization is required for approval of twelve (12) units of CPT code 90870 and will be granted only when all clinical criteria for initiation are documented and met.

    • Prior authorization required for initial ECT: approval of twelve (12) units of CPT 90870 when Initial Authorization Requirements are met
    • Initial Authorization Requirements summary: DSM primary diagnosis (Major Depressive Disorder, Bipolar Disorder, Schizophrenia spectrum, Catatonia, or Neuroleptic Malignant Syndrome); reasonable expectation of benefit; complete diagnostic psychiatric evaluation prior to initiation; one of the following: two or more adequate trials of full‑dose antidepressants (adequate time = 8 weeks) with consideration/attempt of augmentation OR inability to tolerate medications OR marked impairment with high risk of serious complications OR history of significant prior response to ECT; typical acute frequency ~3–5 times/week (commonly 3/week); informed consent and education documented
    • Provider must document informed consent/guardian consent and education on risks/benefits, post‑discharge care, activity restrictions, and transportation/continuation planning
    • Attending physician must be a psychiatrist credentialed to administer ECT and must complete face‑to‑face diagnostic evaluation and maintain documentation

    Background on ECT

    Electroconvulsive Therapy (ECT) is a medical treatment that uses transcranial electrical stimulation to induce a therapeutic seizure with the intent of producing acute and prolonged neurophysiologic changes to improve symptoms of certain psychiatric conditions. It is indicated for disorders including Major Depressive Disorder, Bipolar Disorder, schizophrenia spectrum and other psychotic disorders, catatonia, and Neuroleptic Malignant Syndrome, particularly when rapid benefit is needed, prior treatments have failed, or there is marked impairment.

    ECT is typically delivered under general anesthesia by a psychiatrist trained in ECT and administered in inpatient or outpatient settings. Modern techniques and anesthesia have improved safety and tolerability; the FDA has cleared ECT devices for use in individuals aged 13 and older. An index ECT series commonly includes 6–12 treatments, usually given about 3–5 times per week during the acute course, with continuation treatment available for up to 6 months to prevent relapse and maintenance treatment thereafter in selected patients.

    Key Definitions

    Electroconvulsive Therapy (ECT) definition
    DefinitionElectroconvulsive therapy (ECT) uses an alternating current applied to the scalp to induce a seizure, producing acute and prolonged neuronal changes with therapeutic effects for certain psychiatric conditions
    Historical noteDeveloped in 1938 and continuously refined with advances in devices, stimulus parameters, anesthesia, and muscle relaxants
    Primary therapeutic targetsUsed to improve symptoms of mood disorders, psychosis, and suicidality
    Age and regulatory noteFDA-cleared for use in individuals aged 13 and older; attending and facility must meet applicable state laws/regulations

    Setting and Level-of-Care Considerations

    Treatment Modalities

    inv-16: ECT — treatment modality node

    ECT Indications: ECT indicated for Major Depressive Disorder, Bipolar Disorder, Schizophrenia spectrum disorders, Catatonia, Neuroleptic Malignant Syndrome

    Visit Limits and Quantity Rules

    CPT 90870 — 12 units initially
    CPT code90870 — ECT, general anesthesia
    Initial units approvedTwelve (12) units of CPT code 90870 are considered medically necessary when Initial Authorization Requirements are met
    Associated requirementApproval contingent on meeting all Initial Authorization criteria (diagnosis, evaluation, treatment history, consent, frequency expectations)
    Typical acute frequencyAcute treatment frequency is typically three (3) to five (5) times per week
    Continuation ECT — continuation up to 6 months
    Definition of Continuation ECT periodTreatments provided after the index series for a period of up to six (6) months to individuals in remission

    Policy Revision History

    08/21Original effective date

    Policy originally became effective on 08/21 (Original Effective Date).

    09/22Revision

    Revision to the policy recorded on 09/22 (Revision Dates).

    11/21Review

    Policy review documented on 11/21 (Review Dates).

    Policy Summary
    Payerlucet
    PolicyElectroconvulsive Therapy (ECT) - 2024
    Policy CodePolicy 20.5.002
    Change TypeNo material changes
    Effective DateAug 21, 2024
    Last ReviewSep 23, 2023
    Next Review DateSep 23, 2023
    Key ActionObtain prior authorization documenting required clinical criteria and request twelve (12) units of CPT 90870 for initial ECT when criteria are met.
    SourceLink
    On This Page
    Coverage Criteria for ECTCPT and Coding DetailsProvider Requirements and ActionsBackground on ECTKey DefinitionsSetting and Level-of-Care ConsiderationsTreatment ModalitiesVisit Limits and Quantity RulesPolicy Revision History
    Member expresses a preference for Maintenance ECT OR member is intolerant to pharmacotherapy
    Consent (v): Member or guardian provided informed consent and educated regarding risks and benefits
    Denial Risk

    Denial Triggers

    Triggers for denial. Requests may be denied if required documentation or criteria are missing or not met.

    • Missing or incomplete diagnostic psychiatric evaluation or failure to document a qualifying DSM primary diagnosis
    • No documentation of two or more adequate trials of full‑dose antidepressants (adequate trial = 8 weeks) when indicated, or lack of documented alternative indication (e.g., intolerance to medications, marked impairment, or prior significant ECT response)
    • Absence of documented informed consent (member or guardian) and education regarding risks, benefits, and post‑discharge care
    • Attending physician not identified as a psychiatrist trained/credentialed to administer ECT or lack of face‑to‑face evaluation documentation
    • For continuation requests: lack of documentation of progress toward objective, measurable treatment goals, lack of evidence of improvement or timely re‑evaluation and treatment plan modifications when condition not improving
    SettingGenerally administered on an outpatient basis
    Typical frequency patternTypically starts weekly and then gradually reduces to monthly or longer as clinically stable
    Clinical requirementsAttending psychiatrist must assess symptoms/medications, determine need and timing/frequency; member must have shown adequate response to index episode
    09/23ReviewLatest

    Most recent documented policy review occurred on 09/23 (Review Dates / last review).